Syndax Pharmaceuticals, Inc. (SNDX) Discusses FDA Approval of Revuforj for Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - Slideshow (NASDAQ:SNDX) 2025-10-24

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...